Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06765317 · ClinicalTrials.gov registry record · Phase 2
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
A Phase 2 study of High Grade B-Cell Lymphoma and Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 7
- Study locations
NCT06765317 is a Phase 2 study of High Grade B-Cell Lymphoma and Diffuse Large B Cell Lymphoma (DLBCL) that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 42 participants, below the 61-participant average among 25 other High Grade B-Cell Lymphoma trials with a reported enrollment target (31% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT06765317, a Phase 2 study of High Grade B-Cell Lymphoma and Diffuse Large B Cell Lymphoma (DLBCL), is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study to find out if the study treatment is an effective treatment that causes few or mild side effects in people with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. The treatment being tested in this study is glofitamab, polatuzumab, and obinutuzumab in combination with standard treatment (the combination of rituximab, cyclophosphamide, doxorubicin, and prednisone, or R-miniCHP).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Glofitamab
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Polatuzumab
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-01-16 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06765317
The ClinicalTrials.gov registry entry for NCT06765317 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 25 other High Grade B-Cell Lymphoma trials with a reported enrollment target (31% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with High Grade B-Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06765317 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06765317 about?
NCT06765317 is a clinical study titled "A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma". The researchers are doing this study to find out if the study treatment is an effective treatment that causes few or mild side effects in people with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. The treatment being tested in this study is glofit...
What is the current status of trial NCT06765317?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2025-01-16. Estimated completion is 2028-01.
What conditions does trial NCT06765317 study?
This clinical trial studies the following conditions: High Grade B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL).
What interventions are being tested in trial NCT06765317?
The interventions under investigation include: Cyclophosphamide (DRUG), Glofitamab (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Polatuzumab (DRUG).
Who is sponsoring clinical trial NCT06765317?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06765317 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade B-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RECRUITING · Phase 2
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
High Grade B-Cell Lymphoma
All registered trials for this condition
Diffuse Large B Cell Lymphoma (DLBCL)
All registered trials for this condition
New Jersey
All trials with a study site in New Jersey
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.